Orbis trims Genmab (Nasdaq: GMAB) holding to 4.99% stake

Rhea-AI Filing Summary

Genmab A/S has published a major shareholder notification showing that Orbis Investment Management Limited controls the voting rights to 3,205,763 Genmab shares, equal to 4.99% of the company’s share capital and voting rights as of March 27, 2026. This represents a small decrease from a previous reported position of 5.03% of voting rights. The issuer’s total voting rights and share capital are stated as 64,250,721.

Key Figures

Orbis voting rights: 3,205,763 shares Orbis ownership percentage: 4.9895% Previous Orbis ownership: 5.03% +3 more

6 metrics

Orbis voting rights 3,205,763 shares Voting rights attached to shares in Genmab A/S

Orbis ownership percentage 4.9895% Resulting voting rights position as of March 27, 2026

Previous Orbis ownership 5.03% Voting rights position from prior notification

Total voting rights 64,250,721 Total number of voting rights of Genmab A/S

Threshold crossing date 27-03-2026 Date on which the ownership threshold was reached

Orbis subtotal voting rights 3,205,763; 4.9895% Subtotal 7.1.A in the standard major holdings form

Key Terms

major shareholder announcement, voting rights, Danish Capital Markets Act, financial instruments, +1 more

5 terms

major shareholder announcement financial

"Company Announcement •Major shareholder announcement for Genmab A/S"

voting rights financial

"through shares controlled the voting rights to 3,205,763 shares in Genmab A/S"

Voting rights are the ability of shareholders to have a say in important company decisions, like choosing leaders or approving big changes. They matter because they give owners a voice in how the company is run, similar to how voters influence elections, ensuring the company acts in shareholders’ interests.

Danish Capital Markets Act regulatory

"announces under reference to Section 30 of the Danish Capital Markets Act"

A national law that sets the rules for trading, reporting and oversight of securities and financial markets in Denmark; think of it as the official rulebook that governs how companies, investors and intermediaries must behave when raising capital or trading shares. It matters to investors because it mandates information disclosure, market transparency and conduct standards that reduce fraud, make prices more reliable and protect shareholder rights, helping investors judge risks and make informed decisions.

financial instruments financial

"For notification regarding financial instruments in accordance with section 39(2)(1) of the Capital Markets Act"

Financial instruments are assets or contracts that hold monetary value and can be bought, sold, or traded. They serve as tools for investors to grow, protect, or transfer money, much like how a ticket or voucher can be used to access goods or services. These instruments help individuals and organizations manage financial goals and risks across different markets and economic conditions.

proxy voting financial

"In case of proxy voting, fill out section (9) in the standard form."

Proxy voting is a process that allows investors to have their voting power on company decisions exercised by someone else if they cannot attend meetings in person. It ensures that their opinions are still represented, similar to authorizing someone else to vote on their behalf at an election. This helps investors influence company actions even when they cannot be physically present.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF MARCH 2026

COMMISSION FILE NUMBER 001-38976

Genmab A/S
(Exact name of Registrant as specified in its charter)

Carl Jacobsens Vej 30

2500 Valby

Denmark

+45 70 20 27 28
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F 

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273, 333-284876 and 333-293505) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit			Description of Exhibit
99.1			Company Announcement Dated March 30, 2026
99.2			Orbis Shareholder Notification

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			GENMAB A/S
			BY:			/s/ Anthony Pagano
						Name: Anthony Pagano
						Title: Executive Vice President & Chief Financial Officer

DATE: March 30, 2026

Exhibit 99.1

Major Shareholder Announcement

Company Announcement

•Major shareholder announcement for Genmab A/S

COPENHAGEN, Denmark; March 30, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that, as of March 27, 2026, Orbis Investment Management Limited through shares controlled the voting rights to 3,205,763 shares in Genmab A/S, which amounts to 4.99% of the share capital and voting rights in Genmab A/S.

The major shareholder announcement of Orbis Investment Management Limited is attached to this announcement.

About Genmab

Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.

Contact:    
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs

T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations

T: +45 3377 9558; E: acn@genmab.com

The Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in the Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby, Denmark Tel: +45 7020 2728
www.genmab.com
Company Announcement no. 19 Page 1/1 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122

Shareholder Shareholder 1 / 3 Master data Standard form for notification of major holdings 3. Details of person subject to the notification obligation: Name Allan & Gill Gray Foundation Address Redwood House, St Julian Avenue, GY1 1WA, St Peter Port, GG National ID-number Guernsey Registration Number: 32 Email address gpolkinghorne@allangillgrayphilanthropies.org 4. Full name of shareholder (if different from 3.) The boxes in sections (1-6) and section (8) in the standard form must always be filled out. Section 3 and 4 can be found at the beginning of the form, under master data. Then, please fill out the sections in the standard form for the relevant type of financial instrument. For notification regarding shares go to section (7.1) in the standard form. For notification regarding financial instruments in accordance with section 39(2)(1) of the Capital Markets Act, go to section (7.2) in the standard form. For notification regarding financial instruments in accordance with section 39(2)(2) of the Capital Markets Act, go to section (7.3) in the standard form. In case of proxy voting, fill out section (9) in the standard form. Section 6 is completed automatically when you report your holding in item 7. If there is a holding from a previous notification, this must be indicated below and entered manually. In case of proxy voting, fill out section (9) in the standard form. Other (please specify): An event changing the breakdown of voting rights or share capital An acquisition or disposal of financial instruments An acquisition or disposal of voting rights or share capital 2. Reason for the notification (please tick the appropriate box or boxes): 5. Date on which the threshold was crossed or reached 27-03-2026 6. Total positions of the person subject to the notification obligation: Voting rights: Resulting situation on the date on which threshold was crossed or reached Voting rights attached to shares in % (total of 7.1.A) 4,9895 % Voting rights through financial instruments in % (total of 7.2.A + 7.3.B) 0,00 % The total of both in % (7.1.A + 7.2.A + 7.3.A) 4,9895 % Position of previous notification (if applicable) Voting rights attached to shares in % (total of 7.1.A) 5,03 % Voting rights through financial instruments in % (total of 7.2.A + 7.3.B) 0,00 % The total of both in % (7.1.A + 7.2.A + 7.3.A) 5,03 % Share capital: Resulting situation on the date on which threshold was crossed or reached Share capital attached to shares in % (total of 7.1.B) 0,00 % Share capital attached to shares in % (total of 7.1.B) 0,00 % Share capital attached to shares in % (total of 7.1.B) 0,00 % Position of previous notification (if applicable) 6.A Information on the issuer Total number of voting rights of issuer 64.250.721

Shareholder Shareholder 2 / 3 Total share capital in issuer 64.250.721 7. Specify type of holding Please check the categories below that are relevant for your holding. You can select multiple categories if your portfolio includes different types of instruments or rights. Choose between: Direct shareholding (section 7.1), if you own shares in the company Financial instruments with the right to acquire shares (section 7.2), such as options or forward contracts that give you the right to buy or subscribe for shares Financial instruments with similar economic effect (section 7.3), such as cash-settled derivatives or other instruments that reflect the value of the shares without physical delivery For each category, you must specify whether your holding relates to (A-sections) and/or (B-sections).voting rights share capital If you are unsure which categories apply to you, we recommend that you consult capital markets legislation or seek advice. 7.1 Shares according to section 38 of the Capital Markets Act 7.1.A Holding of voting rights attached to shares ISIN code GENMAB A/S Number of voting rights Voting rights stated in % Voting rights which the person subject to the notification obligation holds directly or indirectly (Sect. 38(1) of the Capital Markets Act) 3.205.763 Voting rights which the person subject to the notification obligation holds directly or indirectly (Sect. 38(1) of the Capital Markets Act) 4,9895 % Voting rights which the person subject to the notification obligation is entitled to acquire, dispose of or exercise (Sect. 38(2) of the Capital Markets Act 0 Voting rights which the person subject to the notification obligation is entitled to acquire, dispose of or exercise (Sect. 38(2) of the Capital Markets Act) 0,00 % SUBTOTAL 7.1.A Number of voting rights 3.205.763 Voting rights stated in % 4,9895 % 7.1.B: Share capital attached to shares 7.2 Financial instruments according to section 39(2)(1) of the Capital Markets Act 7.2.A: Voting rights attached to financial instruments according to section 39(2)(1) of the Capital Markets Act 7.2.B: Share capital attached to financial instruments according to section 39(2)(1) of the Capital Markets Act 7.3 Financial Instruments with similar economic effect acc. to sect. 39(2)(2) of the Capital Markets Act 7.3.A: Voting rights attached to financial instruments according to section 39(2)(2) of the Capital Markets Act 7.3.B: Share capital attached to financial instruments according to section 39(2)(2) of the Capital Markets Act

Shareholder Shareholder 3 / 3 Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity The person subject to the notification obligation is not controlled by any natural person or legal entity and does not xii control any undertaking(s) with holdings in the (underlying) issuer 8. Chain of controlled undertakings (please tick the appropriate box): Name Allan & Gill Gray Foundation Total voting rights if more than 5% Total share capital if more than 5% Name Orbis Allan Gray Limited Total voting rights if more than 5% Total share capital if more than 5% Name Orbis Holdings Limited Total voting rights if more than 5% Total share capital if more than 5% Name Orbis Investment Management Limited Total voting rights if more than 5% Total share capital if more than 5% 9. In case of proxy voting Name of the proxy holder % and number voting rights Date 10. Additional information Orbis Investment Management Limited is an investment manager which has investment discretion and voting control over the Genmab A/S shares and ADRs held by certain investment funds and portfolios. ⭐The reporting party guarantees the accuracy of the information provided.

FAQ

What major shareholding did Orbis report in Genmab (GMAB)?

Orbis Investment Management Limited reported voting rights to 3,205,763 Genmab A/S shares, representing 4.99% of the company’s share capital and voting rights. This stake is held through shares over which Orbis has investment discretion and voting control for certain funds and portfolios.

How did Orbis’s ownership in Genmab (GMAB) change in this filing?

The notification shows Orbis’s voting rights position moving from 5.03% previously to 4.9895% of Genmab’s voting rights. This reflects a slight reduction that brought Orbis just under the 5% major shareholding threshold defined under the Danish Capital Markets Act disclosure rules.

When did Orbis cross the 5% threshold in Genmab (GMAB)?

The threshold event occurred on March 27, 2026, when Orbis’s voting rights position in Genmab reached 4.9895%. This triggered a mandatory major shareholder notification under Section 30 of the Danish Capital Markets Act, which Genmab subsequently published in this report.

How many total voting rights does Genmab (GMAB) have outstanding?

The issuer information in the notification states that Genmab A/S has a total of 64,250,721 voting rights and an equal total share capital figure. Orbis’s 3,205,763 voting rights therefore correspond to 4.9895% of these total voting rights in the company.

Who is the ultimate reporting party in this Genmab (GMAB) stake disclosure?

The master data identify the Allan & Gill Gray Foundation as the person subject to the notification obligation, with Orbis Investment Management Limited in the chain of controlled undertakings. Orbis acts as investment manager with investment discretion and voting control over the relevant Genmab shares and ADRs.

Does Orbis hold Genmab (GMAB) through financial instruments or only shares?

The notification specifies that Orbis’s position in Genmab is held entirely through shares, with 3,205,763 voting rights attached to shares. It reports 0.00% voting rights through financial instruments and 0 voting rights under the relevant Capital Markets Act derivatives sections.

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 14.9 KB
• EX-99.2 EX-99.2 7.7 KB